What Is Ahzantive and How Does It Affect Ophthalmology Billing?
As of late August 2026, the FDA approved Ahzantive (aflibercept-mrbb), an interchangeable biosimilar to Eylea (aflibercept), for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, and diabetic retinopathy. For ophthalmology practices that buy and bill anti-VEGF injections, this approval adds another product to the formulary landscape with its own HCPCS code, ASP-based reimbursement, and payer coverage rules.
Interchangeable status: Ahzantive is approved as an interchangeable biosimilar, meaning it can be substituted for Eylea at the pharmacy level without prescriber intervention in states that allow biosimilar substitution.
Billing impact: Each biosimilar receives its own HCPCS J-code and its own ASP, which means the buy-and-bill margin may differ from the reference product depending on the acquisition cost and the payer’s reimbursement formula.
Payer coverage: Practices need to confirm whether each payer covers the biosimilar, whether it is on the preferred formulary, and whether prior authorization requirements differ from the reference Eylea.
What the FDA Approved
The FDA approved Ahzantive (aflibercept-mrbb), manufactured by Formycon, as an interchangeable biosimilar to Regeneron’s Eylea (aflibercept). The approval covers the same indications as the reference product: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), and diabetic retinopathy (DR).
Ahzantive joins a growing group of FDA-approved aflibercept biosimilars that have entered the market since 2024. Each biosimilar carries its own nonproprietary name suffix and its own HCPCS billing code, which means that even though the clinical product is equivalent, the billing, reimbursement, and payer coverage pathways are distinct for each one.
In our experience matching ophthalmology practices with billing partners, the biggest operational challenge with biosimilars is not the clinical switchover but the billing workflow behind it. Each new product requires its own J-code in the charge capture system, its own ASP-based reimbursement rate, its own prior authorization pathway with each payer, and its own inventory and waste tracking. Practices that treat a biosimilar as a simple drug substitution without updating the billing workflow are the ones that run into denials and reimbursement shortfalls.
Does This Affect Retina and Ophthalmology Practices?
Yes. Any practice that administers intravitreal anti-VEGF injections and bills under Medicare Part B’s buy-and-bill model is directly affected by this approval. Retina practices are the primary users, but comprehensive ophthalmologists who inject for wet AMD, DME, or RVO are also in scope.
The buy-and-bill model means the practice purchases the drug, administers it, and bills the payer for both the drug and the injection service (CPT 67028). The drug reimbursement under Medicare Part B is based on the average sales price (ASP) plus a percentage. Because each biosimilar has its own ASP, the margin between what the practice pays to acquire the drug and what Medicare reimburses can vary significantly across products. A biosimilar with a lower acquisition cost but the same ASP-based reimbursement formula may offer a better margin than the reference product, while a biosimilar with aggressive payer discounting could compress the margin. Retina practices monitoring anti-VEGF margins alongside their OCT imaging volume (92134) and injection scheduling are the ones positioned to make this decision with data rather than guesswork.
Anti-VEGF Products Available for Retina Billing
The table below maps the current anti-VEGF landscape as of September 2026, showing the reference products and their approved biosimilars with billing identifiers.
| Product | Type | Reference | Billing note |
|---|---|---|---|
| Eylea (aflibercept) | Reference biologic | N/A | J0178; established ASP |
| Ahzantive (aflibercept-mrbb) | Interchangeable biosimilar | Eylea | Own J-code; own ASP |
| Lucentis (ranibizumab) | Reference biologic | N/A | J2778; established ASP |
| Vabysmo (faricimab) | Novel biologic | N/A | J3490/J3590 until unique code |
| Avastin (bevacizumab) | Off-label (compounded) | N/A | J9035; compounding rules apply |
Every new anti-VEGF biosimilar adds a J-code, an ASP, and a set of payer coverage rules to your charge capture workflow. If your team cannot track which product each payer covers and at what reimbursement rate, a billing partner who specializes in ophthalmology drug billing can close that gap. Get matched with vetted ophthalmology billing companies, free.
What Should Practices Do Now?
Across the billing companies we vet, the practices that handle biosimilar launches smoothly are the ones that treat it as a billing workflow update, not just a pharmacy decision.
- Confirm the HCPCS J-code. Each biosimilar gets its own J-code. Verify the correct code for aflibercept-mrbb before submitting claims. Using the reference product’s J-code for a biosimilar will result in a denial.
- Check payer coverage for Ahzantive. Contact your top payers and confirm whether aflibercept-mrbb is on their formulary, whether prior authorization requirements differ from Eylea, and whether step therapy applies.
- Update your charge capture system. Add the new J-code, NDC, and dosage information to your practice management system so the correct drug is billed when Ahzantive is administered.
- Model the buy-and-bill margin. Compare the acquisition cost of the biosimilar against the ASP-based reimbursement. A lower acquisition cost with a comparable reimbursement rate improves the margin per injection.
- Track waste and unused drug. Medicare requires reporting wasted or discarded single-use vial amounts. Confirm the vial size and waste reporting requirements for the biosimilar.
- Train injection staff on the new product. Even though the clinical product is equivalent, the label, packaging, and storage requirements may differ. Staff need to know which product is being administered for accurate charge capture.
Common Biosimilar Billing Mistakes
One question we hear constantly from practice managers is whether they can bill a biosimilar with the reference product’s J-code. The answer is no. Each biosimilar has its own HCPCS code, and billing the wrong one is an automatic denial.
- Using the reference J-code. Billing Ahzantive under Eylea’s J0178 will deny. Each product has its own code.
- Assuming all payers cover every biosimilar. Payer formularies vary. Some payers prefer the reference, some prefer a specific biosimilar, and some require step therapy. Verify before administering.
- Not updating ASP expectations. Biosimilar ASPs are published quarterly by CMS. The reimbursement rate changes as the ASP data updates, so the margin on a biosimilar is not static.
- Ignoring the inventory tracking requirement. When multiple anti-VEGF products are in the drug fridge, charge capture must match the specific product administered. A mismatch between the drug given and the drug billed is a compliance issue.
In-House Drug Billing vs. a Partner
Providers often come to us after a payer denies a batch of biosimilar claims because the wrong J-code was submitted or the prior authorization was obtained for the reference product but the biosimilar was administered. These are workflow problems, not coding errors, and they multiply as the number of available biosimilars grows. A billing partner with direct ophthalmology experience already tracks which biosimilars each payer covers, manages the J-code updates as new products launch, and reconciles drug inventory against billed claims. For practices evaluating whether to manage this in-house, our guide on finding the right ophthalmology billing service covers the key criteria.
Frequently Asked Questions
Ahzantive (aflibercept-mrbb) is an FDA-approved interchangeable biosimilar to Eylea (aflibercept), manufactured by Formycon. It is approved for neovascular AMD, diabetic macular edema, macular edema following RVO, and diabetic retinopathy, the same indications as the reference product.
No. Each biosimilar receives its own HCPCS J-code. Billing Ahzantive under Eylea’s J0178 code will result in a claim denial. Verify the correct J-code for aflibercept-mrbb before submitting claims.
Medicare Part B reimburses biosimilars based on the biosimilar’s own ASP plus a percentage. The ASP is specific to each product and is updated quarterly by CMS. The margin depends on the difference between the practice’s acquisition cost and the ASP-based payment.
Potentially yes. Each payer sets its own prior authorization requirements for biosimilars. Some payers require PA for the biosimilar even if the reference product was previously authorized. Verify with each payer before switching products.
Interchangeable status means the biosimilar can be substituted for the reference product at the pharmacy level without prescriber intervention. For buy-and-bill under Part B, the practice decides which product to administer, and each product must be billed under its own J-code regardless of interchangeability.
Multiple aflibercept biosimilars have been approved since 2024. Each has its own nonproprietary name suffix, HCPCS code, and ASP. The number of available products continues to grow, which makes formulary tracking a growing operational requirement.
Next Steps
- Review how anti-VEGF injection billing works alongside diagnostic imaging with our guide on CPT 92134 OCT billing, the most common same-day pairing in retina practices.
- Confirm your top payers’ formulary status for Ahzantive before stocking the product.
- Ready to hand drug billing off? Get matched with an ophthalmology billing company that already tracks biosimilar J-codes, payer formularies, and ASP updates across every anti-VEGF product.
Every new biosimilar adds complexity to your drug billing workflow. Whether you need a billing partner who tracks J-codes and payer formularies across every anti-VEGF product or want to audit your current drug billing accuracy, Ophthalmology Bill Co connects you with vetted partners at no cost. More than 2,000 providers matched, all 50 states, over 15 years in medical billing, rates from 2.95 percent. Matching is 100 percent free.
